Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-7624 in healthy volunteers
NCT06920693Phase 1Active, not recruiting
- Sponsor
- Generate Biomedicines
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GB-7624 in atopic dermatitis (AD) (10 cohorts), sponsored by Generate Biomedicines. Primary endpoints: Safety and tolerability of single doses of GB-7624 at 360 days and Safety and tolerability of multiple doses of GB-7624 at 360 days. Started Mar 2025; status: active, not recruiting.
02
Drugs
GB-7624
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06920693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920693.